,
Article History
Received: 6 June 2019
Accepted: 2 July 2019
First Online: 30 July 2019
Ethics approval and consent to participate
: Not applicable.
: CF is member of the Scientific Advisory Board of Owlstone Medical, and scientific advisor for Istesso LTD.AYR is a SAB member of FLX Bio, Vedanta Biosciences, BioInvent, Surface Oncology and a co-founder of Sonoma Therapeutics. He holds stock options in FLX Bio and Vedanta Biosciences and hold stocks in Surface Oncology.ODKM is an inventor on CRUK patent application GB1603098.3.RMM is supported by a Cancer Research UK program grant (C18281/A19169) and the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.